Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
85 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
RSS Create an RSS feed from your search for:
myeloma AND (women OR woman OR female)
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Dendritic Cell Tumor Fusion
2 Active, not recruiting Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide
3 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
4 Recruiting Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
5 Active, not recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
6 Terminated A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: 5.0g SRT501;   Drug: Bortezomib
7 Active, not recruiting Agriculture Health Study
Conditions: Prostate Cancer;   Pesticide Exposure;   Lymphoma;   Multiple Myeloma
Intervention:
8 Completed Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Bendamustine;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin;   Drug: Prophylaxis;   Drug: Antibiotic;   Other: Biweekly Follow Up;   Other: Cyclical Follow Up;   Other: Restaging;   Other: Post-Treatment Follow Up
9 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
10 Completed S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
Conditions: Multiple Myeloma;   Smoldering Myeloma;   Waldenstrom's Macroglobulinemia;   Monoclonal Gammopathy of Undetermined Significance;   Amyloidosis
Intervention: Other: biologic sample preservation procedure
11 Active, not recruiting Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
Condition: Newly Diagnosed Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Active, not recruiting Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone
13 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
14 Active, not recruiting S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
15 Completed Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone;   Drug: thalidomide
16 Suspended Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
17 Active, not recruiting Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Conditions: Breast Adenocarcinoma;   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   Metastatic Malignant Neoplasm to the Bone;   Pain;   Musculoskeletal Complication;   Urinary Complications
Intervention: Drug: zoledronic acid
18 Unknown  Busulfan and Melphalan Conditioning in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: BUSULFEX®;   Drug: Alkeran®
19 Active, not recruiting
Has Results
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bortezomib;   Drug: Dexamethasone
20 Active, not recruiting
Has Results
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Smoldering Plasma Cell Myeloma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years